Daewoong Co., Ltd.

KOSE:A003090 Stock Report

Market Cap: ₩754.0b

Daewoong Past Earnings Performance

Past criteria checks 1/6

Daewoong has been growing earnings at an average annual rate of 12.6%, while the Pharmaceuticals industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 8.1% per year. Daewoong's return on equity is 4.6%, and it has net margins of 3%.

Key information

12.6%

Earnings growth rate

13.3%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate8.1%
Return on equity4.6%
Net Margin3.0%
Last Earnings Update31 Dec 2024

Recent past performance updates

Daewoong's (KRX:003090) Soft Earnings Don't Show The Whole Picture

Mar 14
Daewoong's (KRX:003090) Soft Earnings Don't Show The Whole Picture

Recent updates

Daewoong's (KRX:003090) Soft Earnings Don't Show The Whole Picture

Mar 14
Daewoong's (KRX:003090) Soft Earnings Don't Show The Whole Picture

These 4 Measures Indicate That Daewoong (KRX:003090) Is Using Debt Extensively

Nov 11
These 4 Measures Indicate That Daewoong (KRX:003090) Is Using Debt Extensively

Daewoong Co., Ltd. (KRX:003090) Held Back By Insufficient Growth Even After Shares Climb 26%

Sep 01
Daewoong Co., Ltd. (KRX:003090) Held Back By Insufficient Growth Even After Shares Climb 26%

Daewoong Co., Ltd.'s (KRX:003090) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 14
Daewoong Co., Ltd.'s (KRX:003090) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Is Daewoong (KRX:003090) Using Too Much Debt?

Jul 04
Is Daewoong (KRX:003090) Using Too Much Debt?

Does Daewoong (KRX:003090) Have A Healthy Balance Sheet?

Apr 02
Does Daewoong (KRX:003090) Have A Healthy Balance Sheet?

With EPS Growth And More, Daewoong (KRX:003090) Is Interesting

Apr 13
With EPS Growth And More, Daewoong (KRX:003090) Is Interesting

A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)

Mar 29
A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)

Daewoong Co., Ltd. (KRX:003090) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Mar 14
Daewoong Co., Ltd. (KRX:003090) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Daewoong (KRX:003090) Seems To Use Debt Quite Sensibly

Feb 21
Daewoong (KRX:003090) Seems To Use Debt Quite Sensibly

The Daewoong (KRX:003090) Share Price Has Soared 308%, Delighting Many Shareholders

Jan 31
The Daewoong (KRX:003090) Share Price Has Soared 308%, Delighting Many Shareholders

Do Its Financials Have Any Role To Play In Driving Daewoong Co., Ltd.'s (KRX:003090) Stock Up Recently?

Dec 04
Do Its Financials Have Any Role To Play In Driving Daewoong Co., Ltd.'s (KRX:003090) Stock Up Recently?

Revenue & Expenses Breakdown

How Daewoong makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A003090 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 241,936,91757,886574,296176,049
30 Sep 241,880,071123,360571,799176,459
30 Jun 241,825,714118,195553,511178,268
31 Mar 241,821,844135,340556,384174,025
31 Dec 231,813,841152,665545,492176,599
30 Sep 231,811,723123,0491,277,14986,522
30 Jun 231,783,012122,6471,026,003114,576
31 Mar 231,735,656117,547523,653174,207
31 Dec 221,697,338102,566508,915169,887
30 Sep 221,657,478124,723494,921154,728
30 Jun 221,600,944112,646466,976146,440
31 Mar 221,560,37799,018450,442140,967
31 Dec 211,511,37478,730431,966134,260
30 Sep 211,451,197105,593406,842131,571
30 Jun 211,428,06894,024399,184131,845
31 Mar 211,375,58186,028388,795126,820
31 Dec 201,355,33798,379395,876118,851
30 Sep 201,362,72949,531398,011121,791
30 Jun 201,343,95745,569408,601117,515
31 Mar 201,375,38465,058404,966119,113
31 Dec 191,365,67961,493388,752123,955
30 Sep 191,339,50241,771367,893221,824
30 Jun 191,313,89844,530340,753193,494
31 Mar 191,261,87927,355324,180128,659
31 Dec 181,231,29029,863311,280130,618
30 Sep 181,186,05968,359306,70429,483
30 Jun 181,171,37268,406304,56262,989
31 Mar 181,149,16467,927297,593128,220
31 Dec 171,123,95766,251296,164120,546
30 Sep 171,113,71153,527-124,649123,106
30 Jun 171,076,12449,1878,680116,986
31 Mar 171,036,11334,188272,908110,977
31 Dec 161,014,96619,831269,777112,694
30 Sep 16996,88510,688679,958101,229
30 Jun 161,002,59211,074537,78282,801
31 Mar 16997,33225,784260,64662,137
31 Dec 15996,75738,623253,16540,865
30 Sep 15978,60035,386252,06829,911
30 Jun 15945,03726,648248,92026,886
31 Mar 15925,51124,480123,80828,020
31 Dec 14893,95323,811241,88927,461
30 Sep 14879,69925,540257,93026,177
30 Jun 14866,07236,765251,23626,574

Quality Earnings: A003090 has a large one-off loss of ₩42.0B impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: A003090's current net profit margins (3%) are lower than last year (8.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A003090's earnings have grown by 12.6% per year over the past 5 years.

Accelerating Growth: A003090's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A003090 had negative earnings growth (-62.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.7%).

Return on Equity

High ROE: A003090's Return on Equity (4.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/08 06:59
End of Day Share Price 2025/04/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daewoong Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyonseok KimCLSA
Bora ChungDaishin Securities Co. Ltd.
Jonghyun ParkDAOL Investment & Securities Co., Ltd.